US 12,214,052 B2
Nanoparticle platform for antibody and vaccine delivery
Jean-Philippe Julien, Toronto (CA); Taylor Sicard, Toronto (CA); Anthony Semesi, Toronto (CA); Bebhinn Treanor, Toronto (CA); Tiantian Zhao, Toronto (CA); and Edurne Rujas Diez, Toronto (CA)
Assigned to The Hospital for Sick Children, Toronto (CA); and The Governing Council of the University of Toronto, Toronto (CA)
Appl. No. 16/636,141
Filed by The Hospital for Sick Children, Toronto (CA); and The Governing Council of the University of Toronto, Toronto (CA)
PCT Filed Aug. 3, 2018, PCT No. PCT/CA2018/050954
§ 371(c)(1), (2) Date Feb. 3, 2020,
PCT Pub. No. WO2019/023811, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/541,209, filed on Aug. 4, 2017.
Prior Publication US 2020/0179532 A1, Jun. 11, 2020
Int. Cl. A61K 47/69 (2017.01); A61K 39/015 (2006.01); A61K 47/68 (2017.01); C07K 14/445 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 47/6929 (2017.08) [A61K 39/015 (2013.01); A61K 47/68 (2017.08); C07K 14/445 (2013.01); B82Y 5/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/735 (2013.01)] 7 Claims
 
1. A fusion protein comprising an antibody fragment consisting of a single-chain Fc (scFc), wherein the antibody fragment is fused to a nanocage monomer via a linker.